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Abstract
The chapter discusses the current understanding of the system of mineral and bone 
metabolism regulators—FGF-23, Klotho and sclerostin—disturbances in chronic kidney 
disease (CKD). In the chapter we presented the date, including our own results, which 
allow to suggest the change in the ratio of FGF-23-Klotho-sclerostin in CKD as an early 
biomarker not only for the chronic kidney damage but also for high cardiovascular (CV) 
risk. Results of studies show that disorders in FGF-23-Klotho-sclerostin ratio correlate 
with the frequency and severity of hypertension, vascular calcification, cardiac remodel-
ling, anaemia, malnutrition, inflammation and strong aggravate CV risk in CKD. It was 
found independent from blood pressure (BP) action of increased serum FGF-23 on the 
myocardium as well as the correlation of serum high-sensitive troponin I with increased 
serum FGF-23 and low Klotho levels in CKD patients. At the same time, it was shown 
that renoprotective therapy, including renin-angiotensin blockers, low-protein diet with 
amino/keto acid supplementation and phosphate binders, erythropoiesis stimulators, 
vitamin D metabolites used to get the target levels of BP, serum phosphorus, haemoglo-
bin, parathyroid hormone and nutritional status disorders correction can reduce the risk 
of CV events, as the major cause of death in CKD patients.
Keywords: chronic kidney disease, FGF-23, Klotho, sclerostin, vascular calcification, 
cardiac remodelling
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1. Introduction
Chronic kidney disease (CKD) is a global problem that has not only medical but also great 
social and economic importance, due to a significant prevalence in the population (10–15%), 
high mortality rate from cardiovascular complications (CVC), as well as the need for high-cost 
treatment for the end CKD stage (dialysis, transplantation). As compared with general popu-
lation, mortality rate due to CVC in patients with chronic renal failure is 10 times higher, and 
in young people, this risk is higher by 100 or more time. Many patients with CKD die from 
CVC on pre-dialysis stages, not reaching the end stage of CKD [1, 2].
Among cardiovascular damage in CKD, the progressive both cardiac remodelling and vascu-
lar calcification have leading contribution, which together lead to an urgently high cardiovas-
cular mortality in patients with CKD [3, 4]. Understanding of the early mechanisms of arterial 
calcification as well as left ventricular hypertrophy (LVH) is important for the development of 
new therapeutic strategies aimed for cardiovascular morbidity reducing, pre-dialysis period 
prolonging and overall survival of CKD patients improving.
Clarification of CKD progression mechanisms and possible early markers of CVC has led to 
interest in studying of the identified in recent years factors such as morphogenetic proteins—
fibroblast growth factor-23 (FGF-23), Klotho protein and sclerostin glycoprotein—which were 
estimated initially only as bone-mineral metabolism regulators in CKD [5].
Nowadays, the broader functional role of FGF-23, Klotho and sclerostin in organism has 
become understandable, including them significance as humoral factors involved in the pro-
cesses of remodelling and calcification of the heart and vessels in CKD [6, 7]. Furthermore, the 
accumulated recently data allow to consider these factors as a possible therapeutic option for 
reducing mortality in CKD patients, but new randomized trials are still needed to clarify the 
individual mechanisms of their influence on remodelling and calcification of the heart and 
blood vessels as well as the optimal therapeutic modalities for correction of these disturbances.
The aim of the review was to systematize accumulated information and to establish the signif-
icance of the changes in serum levels of morphogenetic proteins (FGF-23, Klotho) and scleros-
tin glycoprotein, based on available literature data, including the results of our own studies, 
to assess renal and cardiac prognosis and possibilities for improving of cardio-renoprotective 
strategy in CKD.
2. FGF-23, Klotho and sclerostin in mineral bone disorders (MBD) 
in CKD
Disorders of phosphorus-calcium metabolism begin to be detected already on the 3A stage 
of CKD, when serum phosphorus starts to increase in serum due to glomerular filtration rate 
(GFR) decreasing [8]. PTH and vitamin D (calcitriol) were considered as main phosphor-reg-
ulating hormones for a long time. However, in recent years, it has been established, including 
our data, that FGF-23 begins to increase in serum in response to phosphorus retention, earlier 
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than PTH [8, 9], that allows to reconsider the traditional concept of secondary hyperparathy-
roidism (SGPT) pathogenesis.
FGF-23, produced by osteocytes, is a phosphaturic hormone that maintains a normal serum 
phosphorus concentration by increasing excretion of phosphorus in the urine and reducing 
its absorption from the gastrointestinal tract by inhibiting synthesis of 1,25-dihydroxyvitamin 
D in kidneys. Physiological stimuli for FGF-23 secretion are both a diet with an excess of phos-
phorus content and an increase in 1,25(OH)
2
D
3
 levels in circulation [5, 8]. In the kidneys, FGF-
23 suppresses 1,25(OH)
2
D
3
 formation by inhibiting 1α-hydroxylase enzyme activity, which 
converts 25(OH)D
3
 transition to 1,25(OH)
2
D
3
, as well as FGF-23 stimulates the formation of 
24-hydroxylase, which converts 1,25(OH)
2
D
3
 into its inactive metabolites. At the same time, 
FGF-23 suppresses the expression of the sodium-phosphorus co-transporters of both types 
(IIa and IIc) located on the apical surface of the epithelial cells of the proximal renal tubules; 
as a result, renal excretion of phosphorus increases [5, 8, 10].
At the same time, a date on the direct blocking effect of FGF-23 on PTH secretion was obtained 
[11]. It was found that FGF-23 stimulates mitogen-activated protein kinase (PKA) pathway, 
and so it inhibits the expression of PTH mRNA and PTH secretion both in vivo in rats and in 
vitro in parathyroid cell culture [11]. Since PTH is the inducer of 1,25(OH)
2
D
3
 gene expression, 
the suppression of PTH, caused by FGF-23, reduces the serum level of 1,25(OH)
2
D
3
, thereby 
closing the negative feedback of vitamin D homeostasis.
As the renal 1α-hydroxylase is inhibited and secretion of 1,25(OH)
2
D
3
 is decreased, hypocal-
caemia occurs, which stimulates PTH overproduction [12]. Thus, normal levels of calcium 
and phosphorus in serum are maintained that is successful at the early CKD stages.
Initially, at the early CKD, the increase in FGF-23 is a compensatory response aimed at nor-
malizing phosphorus serum levels while decreasing the functioning nephron number [8, 12]. 
The serum FGF-23 level increases in parallel with the progressive decrease in kidney function, 
and the serum phosphorus does not increase significantly until GFR falls <30 mL/min/1.73 m2 
[5, 8]. When this stage of CKD is reached, the above compensation mechanism becomes inef-
fective, and constant hyperphosphatemia occurs that stimulates the increasing secretion of 
FGF-23 and PTH [8]. By the time when patients reach the end stage of CKD, FGF-23 level 
exceeds its normal range by 100 or more times [8].
To realize its effects in the kidneys, FGF-23 needs a co-receptor which is a transmembrane 
form of Klotho protein [5, 10]. Klotho was originally identified as an “ageing suppressor” 
[13]. The Klotho gene encodes a transmembrane protein, which is expressed predominantly 
in the epithelial cells of distal tubules in the kidneys, in parathyroid glands (PTG) and in 
the cerebral vascular plexus. Two forms of Klotho protein were found: transmembrane and 
secreted forms, each of which has different functions. The membrane Klotho form acts as an 
obligate co-receptor for FGF-23, inducing the excretion of phosphate in the urine. Secreted 
Klotho form (sKlotho) is detected in human serum and cerebrospinal fluid. It was found that 
it is formed as a result of Klotho protein cleavage from the cell membrane of the distal tubules 
of the kidneys [5, 10]. The decrease of Klotho protein expression in the kidneys due to CKD 
advancement allows to consider it as an early diagnostic marker of kidney damage [5, 14].
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Unlike the membrane form, the secreted form of Klotho has systemic effects: it regulates 
endothelial production of NO [15], maintains the integrity and permeability of the endothe-
lium [16] and calcium homeostasis in the kidneys [17] and suppresses intracellular signals 
of insulin and insulin-like growth factor-1 as mechanisms evolutionarily associated with life 
expectancy [18]. The low serum level of sKlotho is associated with an increase of CVC [6] and 
all causes mortality [19].
In recent years, there is increasing evidence that sKlotho decreasing, as CKD advancement, 
occurs early (2–3A stage of CKD) and may be also an important reason for the inducing of 
FGF-23 serum increase. Koh et al. [20], based on the analysis of the kidney biopsy that results 
in ten patients with a histological nephrosclerosis, found a significant decrease in the expres-
sion of Klotho mRNA as well as in sKlotho level and also the role of Klotho deficiency as 
nephrosclerosis advances, in the development of numerous complications of CKD, including 
uncontrolled FGF-23 serum increase.
The reduced expression of Klotho transmembrane form on the surface of parathyroid glands 
(PTGs) cell membranes (Klotho is also a co-receptor for FGF-23 in PTGs) at advanced stages 
of CKD is attributed to the resistance of PTG receptors to FGF-23, even in FGF-23 maximum 
concentrations [10, 12, 21].
In recent years, data on the important role of sclerostin glycoprotein in CKD are accumulat-
ing [22, 23]. Sclerostin, synthesized by osteocytes, blocks Wnt signalling pathway that leads to 
suppression of bone formation, as a result of decreased osteoblast differentiation and prolifer-
ation and osteocyte apoptosis [24]. The level of sclerostin increases as CKD advances [22, 25].
To date, sclerostin is an established regulator of bone mineralization, while its role in the 
pathophysiology of vessels in CKD is actively explored [22, 26]. It is important to determine 
the clinical significance of changes in sclerostin metabolism in CKD, because the relationship 
between adynamic bone disease (ABD) and calcification of the heart and blood vessels in 
patients with CKD is considered proven [27]. At the same time, available-to-date publications 
on the role of sclerostin in ectopic calcification still remain contradictory [22, 23, 25, 26].
It has been shown in experimental studies that in the case of hyperphosphatemia, the function 
of the skeleton as a phosphorus reservoir is blocked, although the need of bone in phospho-
rus, on the contrary, is increased, which stimulates a rising of its level in the blood, and soft 
tissues and vessels become a new reservoir for phosphate deposition [27].
Thus, in patients with end CKD stages, hyperphosphatemia, Klotho’s and 1,25(OH)
2
D
3
 defi-
ciency and increased PTH and sclerostin occur, despite a very high level of FGF-23. At the 
same time, the frequency of ABD associated with a relatively low PTH and high sclerostin 
serum levels increases [12, 24, 27]. These changes, together with a decreased calcium excre-
tion, may be responsible for the development of such complications of CKD as renal osteodys-
trophy, cardiovascular calcification following CVC and adverse outcomes in CKD [6, 7, 26].
It is suggested that an increase in sclerostin serum levels leads to a slowdown in osteogenesis 
in CKD. At the same time, there are reasons to believe that this mechanism is blocked in CKD 
and an increase in sclerostin is directed mainly to the inhibition of the extraosteal calcification 
[22, 25]. In addition it is believed that an increase in sclerostin expression by osteocytes in 
CKD causes bone resistance to PTH [24].
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According to the results of recent studies, a disorder of the FGF-23-Klotho-sclerostin ratio in 
CKD is an early biomarker of the degree of chronic renal damage, preceded to the changes in 
other established markers of CKD advancement such as hyperphosphatemia, hyperparathy-
roidism and hypovitaminosis D, considering early as emerging cardiovascular risk factors in 
CKD patients [5, 26]. In addition, in interventional trials, intake of phosphate binders, cinacal-
cet or active vitamin D did not exert a consistently beneficial effect to reduce in cardiovascular 
event rate [28].
2.1. The relation of FGF-23, Klotho and sclerostin with cardiovascular remodelling 
and calcification in CKD
Mineral bone disorders (MBD) in CKD are the main contributor in CVC risk and in general 
prognosis of this patient cohort (Figure 1).
If the increase in FGF-23 serum levels at early CKD stages is adaptive, then the rapid FGF-23 
rising from 3B CKD stage acquires a pathological significance. It was shown that an increase 
in serum FGF-23 level in CKD 3B-5 stages is associated with an endothelium dysfunction, Left 
ventricular hypertrophy (LVH) and an increase in cardiovascular mortality [7, 29–31].
It is also believed that a markedly increased FGF-23 level in CKD leads to a non-selective 
binding of it to FGF receptors in the heart, which are usually activated by local growth factors, 
such as FGF-2 [32]. Thus, an elevated FGF-23 level was directly associated with an increased 
risk of LVH development, which was detected with prolonged exposure with FGF-2 in experi-
ment. In addition, it was found that an increase in left ventricular mass index (LVMI) accom-
panied with increased serum FGF-23 was independent from serum phosphorus level [7, 9].
FGF-23 is an earlier, than phosphorus, marker of CVC in patients with CKD, even when 
a phosphorus serum level is within the normal range [8, 9]. The pathogenetic relationship 
Figure 1. The position of MBD among the main causes of mortality in CKD haemodialysis patients (according to Block 
GA et al. J. Am. Soc. Nephrol. 2004).
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between FGF-23 serum level and LVH was fully confirmed in the fundamental clinical work 
of Faul and Ansel [7] which showed that an increase in serum FGF-23 levels can directly 
lead to LVH development in CKD patients. The study consists of several stages; at the first 
stage, more than 3000 patients with renal insufficiency were examined for serum FGF-23 and 
echocardiography (EchoCG) at baseline and 1 year later. Each increase in serum FGF-23 on 
1 logarithmic unit was associated with an increase in LVMI on 1.5 g/m2. After 2.9 ± 0.5 years, 
the researchers re-examined 411 patients who had normal EchoCG parameters at the begin-
ning of the study. In 84 (20%) patients with normal blood pressure (BP) levels, LVH was firstly 
detected. At the same time, each increase in FGF23 on 1 logarithmic unit led to an increase in 
the frequency of LVH de novo detection by 4.4 times; and significantly high levels of FGF-23 
caused a sevenfold increase in the frequency of LVH detection, independently of the arterial 
hypertension (AH).
In order to confirm the hypothesis of the direct influence of FGF-23 on cardiomyocytes, 
Kardami [32] conducted the experimental study in which an effect of exogenous FGF-23 on 
the cardiomyocytes of newborn rats was evaluated using immunohistochemical and morpho-
metric analysis. As a result, the hypertrophy of cardiomyocytes was revealed, as well as the 
increase in them, a level of alpha-actinin protein that indicates an increase of sequentially con-
nected sacrometer units in the cardiomyocytes, and an increase in expression of heavy embry-
onic beta-myosin chains and depression of mature alpha-myosin chains. This switching of 
heavy chains from mature to embryonic isoforms indicates on the reactivation of embryonic 
gene programme, which is associated with hypertrophic transformation.
In the work of Di Marco et al. [33], prohypertrophic effect of FGF-23 and FGF-2 on cardiomyo-
cytes was noted, which disappeared after the use of FGF-23 receptor inhibitor, PD173074, that 
authors consider as evidence of direct FGF-23 action, independently of Klotho protein. It is 
important to note that the use of PD173074 prevented the development of LVH in rats, despite 
the presence of hypertension in them.
According to our data [34], an increase in serum FGF-23 levels was associated with a mod-
erately elevated level of troponin I. At the same time, in the patients with increased central 
BP (>120/80 mm Hg) as well as with normal central BP (90–120/60–79 mm Hg), mean levels 
of FGF-23 were about the same [629 ± 118 and 489 ± 85, respectively], indicating, an indepen-
dent from the BP, FGF-23 action on the myocardium. The association of troponins with isch-
aemic heart disease and their role as predictors of an unfavourable cardiovascular outcome is 
known that also allows to suggest FGF-23 as an important prognostic cardiomarker in CKD.
In addition, it was established [35] that an increase in serum FGF-23 levels accelerated the 
development of vascular arteriosclerosis almost by sixfold, with the direct correlation with 
vascular calcification. However, in multivariate analysis, this relationship was statistically 
weak, which may indicate a possible indirect effect of FGF-23 on vascular calcification. 
Further obtained data indicate the effect of FGF-23 on fetuin A level, which is known to 
be synthesized by osteoblasts and is an inhibitor of vascular smooth muscle cell (VSMS) 
calcification [35, 36].
In the prospective cohort ArMORR study [37] involving 10,044 patients, it was shown 
that a high FGF-23 serum level of patients, starting treatment with programmed HD, is an 
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 independent predictor of annual mortality and the patients with high levels of FGF-23 from 
a higher quartile had a sixfold increase in the risk of mortality compared to similar patients 
from the lower quartile according to multidimensional corrected model.
In another prospective the mild to moderate kidney disease (MMKD) study [38] involving 
227 patients with nondiabetic CKD 1–4 stages, the patients were followed up for 53 months to 
assess the progression of the nephropathy. Based on the results, an independent direct rela-
tionship between increased serum FGF-23 level and CKD progression rate was established. 
FGF-23 was recognized as an important independent predictor of adverse renal and cardio-
vascular prognosis, and in addition, in the regression Cox analysis, phosphorus levels lost 
prognostic value after adjustment to serum FGF-23 level.
Accumulating recent data allow to consider FGF-23 as an earlier and important predictor of 
mortality than serum phosphorus and PTH levels in patients with CKD. Elevated serum FGF-
23 level is currently considered as an independent trigger factor in the pathogenesis of uremic 
cardiomyopathy and vascular calcification that served as the basis for suggesting FGF-23 as a 
new uremic toxin, earlier than PTH [39].
At the same time, part of the pathological effects of FGF-23 may be due to Klotho deficiency in 
CKD advancement. It has been shown that kidneys are the main producers of Klotho forms in 
organism [5, 10, 14], so CKD is a state of Klotho deficiency. Deficit of Klotho causes develop-
ment of multiple systemic manifestations (i.e. premature ageing syndrome), an integral part 
of which is severe cardiovascular impairments [6, 13, 15]. According to recent update, it has 
been proved now that Klotho downregulation is not merely an early biomarker for kidney 
damage but also plays a pathogenic independent role in the advancing of CKD as well as in 
principal complications of CKD, important part of which is vascular calcification [6, 9]. As it 
was recently summarized, Klotho’s anti-calcification effect is possibly via at least three mech-
anisms: a phosphaturic hormone, the preservation of GFR and a direct effect on soft tissues 
including the vascular smooth muscle [6, 21]. In experiment Klotho overexpression slowed 
down CKD advancement, improves phosphate metabolism and protects the vasculature from 
calcification [5, 6, 10].
The role of soluble Klotho form in phosphate homeostasis was recognized as soon as Klotho 
was discovered, because Klotho-deficient mouse demonstrates severe hyperphosphatemia 
[10, 13, 18]. This was further confirmed by the fact that there was low serum phosphate in 
Klotho-overexpressing mice [18]. A patient with homozygous missense mutation (H193R) in 
Klotho gene had severe calcinosis, dural and carotid artery calcifications, severe hyperphos-
phatemia, hypercalcemia and high-serum 1,25(OH)
2
 vitamin D and FGF-23. This mutation 
conceivably destabilizes KL1 domain of Klotho, thereby attenuating production of mem-
brane-bound and sKlotho protein [40]. Therefore, Klotho is now considerable as a novel can-
didate gene for genetic hyperphosphatemia and calcinosis.
It was established that a decrease in Klotho level is also possible due to the inhibition of its 
extrarenal production. In this connection, the results of Takeshita et al. [41] study, indicating 
the presence of Klotho gene expression in sinoatrial node and a high rate of sudden car-
diac death due to arrhythmias caused by dysfunction of sinoatrial node in mice with blocked 
Klotho gene, are interesting.
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One of the most important effects of Klotho and sclerostin is its ability to inhibit Wnt sig-
nal pathway and through it to slow down vascular calcification [42]. Reduction of serum 
Klotho levels impairs this protective effect. Besides this, it has been demonstrated that Klotho 
mitigates the increased cell senescence and apoptosis triggered by oxidative stress in endo-
thelial cells [43] and Klotho also suppresses TNF-β-induced expression of intracellular adhe-
sion molecule-1 and vascular cell adhesion molecule-1, attenuates NF-kappaB activation and 
reverses the inhibition of eNOS phosphorylation by TNF-α. Thus Klotho protein also protects 
the vascular endothelium by inhibition of endothelial inflammation [44].
The most definitive study to date of the direct effects of Klotho on the endothelium was con-
ducted by Kusaba et al. [16]. Klotho-deficient mice have increased VEGF-mediated calcium 
influx, downregulation of vascular endothelial cadherin, increased apoptosis and excessive 
permeability of vessels. The KL2 domain of Klotho protein binds directly to VEGF receptor 
2 and endothelial transient-receptor potential Ca2+ channel 1 on the extracellular side and 
promotes their co-internalization, thereby reducing the Ca2+-activated and caspase-mediated 
destruction of catenin and vascular endothelial cadherin on the cell surface. Thus, it may be 
one more effect of soluble Klotho’s protein cardioprotection.
In vitro studies have shown that along with the increase in phosphaturia, stabilization of 
GFR and regulation of vascular endothelial permeability, Klotho suppresses Na-dependent 
capture of phosphorus by the endothelium and vascular smooth muscle cell (VSMC) and 
prevents differentiation of VSMC and mineralization induced by hyperphosphatemia [5, 14].
In our study, an association of increased serum FGF-23 and low Klotho levels with the presence 
of inflammation (as C-reactive protein level increasing) as well as with protein-energy defi-
ciency, and proteinuria, was found [45]. These data are in agreement with the results of other 
authors [44, 46] who consider CKD as a state of chronic inflammation, based on the consider-
ation of elevated C-reactive protein level as a nonspecific marker of inflammation and endothe-
lial dysfunction in CKD patients. Frequent coexistence triad—malnutrition, inflammation and 
atherosclerosis (MIA) syndrome—contributes to the risk of CVC in CKD [2, 3, 47]. The obtained 
data clearly indicate that circulating form of Klotho protein functions as a humoral factor that 
protects the cardiovascular system from the development of inflammatory endothelial changes 
and prevents the progression of atherosclerosis and pathological calcification [5, 14–16].
Less understood is the role of sclerostin in CV calcification processes in CKD. Our data go in 
agreement with the results of authors, who demonstrated a protective effect of sclerostin in 
calcification in CKD [22, 48, 49]. Its inhibitory effect on osteogenesis and negative association 
of sclerostin with level of parathyroid hormone as uremic toxin can attest in favour of this 
date [48, 49].
Viaene et al. [50] showed that in patients on haemodialysis, the serum concentration of 
sclerostin is higher than in general population. In the future, these data will be repeatedly 
confirmed by the results of other studies devoted to identify the role of sclerostin in patients 
on regular haemodialysis [23, 49].
Emerging evidence indicates that Wnt plays a role in vascular biology including vascular cal-
cification, angiogenesis and atherosclerosis [42]. Wnt signalling occurs when the Wnt ligand 
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binds to co-receptors, Frizzled and low-density lipoprotein receptor-related protein (LRP), 
which induces β-catenin translocation to the nucleus to regulate the transcription of Wnt tar-
get genes. The Wnt pathway is involved in many aspects of biology including cell survival, 
stem cell development and cell differentiation, including bone and vascular lineages [24, 42].
Register et al. [25] found that high sclerostin was associated with less calcified carotid plaque 
in diabetic African American men and was not associated with aortic or coronary calcification. 
Authors’ hypothesis to explain this situation is that increased overproduction of sclerostin 
may be a physiological adaptation to increased calcification.
Sclerostin slows the canonical Wnt signalling pathway and inhibits osteoblast activity and 
bone formation by sequestering LRP5 and LRP6 [24, 42]. Retarding the Wnt signalling path-
way by using a dominant-negative LRP has been depicted to significantly reduce VSMC prolif-
eration. In addition to VSMC proliferation, animal models of intimal thickening have revealed 
increased β-catenin levels, which suggest the involvement of the Wnt-β-catenin pathway also 
in VSMC migration. Moreover, Wnt proteins are also known to promote the migration of 
various cell types, including monocytes and endothelial cells. Furthermore, the Wnt pathway 
has been described to play an important role in the regulation of endothelial inflammation, 
vascular calcification and mesenchymal stem cell differentiation. As a result, considering the 
fact that atherosclerosis and calcification are both an actively regulated and progressive pro-
cess, we might speculate that high sclerostin levels might be indicative of a sort of defensive 
mechanism that may attenuate the upregulation of the canonical Wnt pathway and lead to the 
restoration of quiescent Wnt signalling observed under healthy conditions [24, 49].
Sclerostin has been demonstrated to be upregulated in VSMC, which previously transformed 
into osteocytic phenotype under calcifying circumstances [22, 24]. Recently, it has been sug-
gested that increased circulating sclerostin levels might protect dialysis patients from car-
diovascular calcification and that low bone-specific alkaline phosphatase activity may be the 
causal pathway [23, 49]. Sclerostin is a potent inhibitor of alkaline phosphatase activity, which 
inactivates the potent calcification inhibitor, the inorganic pyrophosphate. Accumulating 
data suggest that Wnt signalling pathway inhibitor overexpression in calcifying vasculature 
(advanced carotid plaques and calcified aortas) might be vasculoprotective and anti-calcific 
[25, 49].
PTH increases FGF-23 expression via Wnt and protein kinase (PKA) signalling pathways by 
blocking the inhibitory effect of sclerostin (Figure 2).
According to several authors, the overexpression of sclerostin by osteocytes in patients on 
haemodialysis is associated with a decrease in overall cause’s mortality, including CVC, in 
dialysis patients [49].
In the same time, more research for confirmation of sclerostin role in FGF-23-Klotho-sclerostin 
system as a protector of pathogenic transformation of VSMC, triggered by phosphate and 
FGF-23, is seen as a priority. It is likely that sclerostin confronts effects of low Klotho levels 
and high levels of FGF-23, allowing for some time to maintain a certain compensatory balance 
in the system of FGF-23-Klotho-sclerostin. Increasing levels of sclerostin in CKD are likely 
directed at suppression of processes of calcification, but cannot fully inhibit them, because 
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reduction of Klotho may be much more potent stimulus for progression of calcification, and 
increased PTH suppresses sclerostin. Because levels of sclerostin increase as CKD progresses 
and as levels of Klotho at the same time reduce, some authors may mistakenly interpret the 
role of sclerostin as a factor, which potentiates calcification. In reality (the results of the mul-
tivariate analysis), it is likely that dramatic fall of Klotho levels in the course of CKD outbal-
ances and levels down protective effects of sclerostin.
To sum up, we can consider all three factors (FGF-23, Klotho, sclerostin) as a discrete 
system of factors influencing cardiovascular risk. Apparently, such high CV risk is deter-
mined by joint effect of all of these three factors that appear along with early CKD stages 
and connect not only between themselves but also with traditional factors, which snow-
balled quickly following added, potentiate one another as CKD advanced and thereby 
strongly increase the risk of CV mortality. Influence of each group of these factors may 
have different impacts depending on the stage of CKD. Importantly, date indeed sug-
gests that the FGF-23-Klotho-sclerostin axis may be a potential novel target in cardio-renal 
medicine.
3. Possibilities for correction of FGF-23, soluble Klotho and sclerostin 
serum disorders in CKD by traditional renoprotective therapy
The appearance preliminary results of few clinical trials indicate the possibility of influencing 
traditional renoprotective therapy such as early correction of arterial hypertension, anaemia, 
Figure 2. The relationship between PTH, FGF-23 and sclerostin (materials of ISN Nexus Symposium «Bone and the 
Kidney» September 2012, Copenhagen, Denmark).
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hyperphosphatasemia and nutritional status disorders on the maintenance of Klotho protein 
synthesis and FGF-23 overproduction suppression [51–53].
Since the serum FGF-23 level (as more earlier marker of MBD than PTH in CKD) rises before 
serum phosphorus increases as CKD advances, a preventive decrease in phosphorus diet con-
tent in CKD patients with elevated serum FGF-23 levels and the use of phosphate-binding 
drugs (for the control of serum phosphorus levels below 6.5 mg/dL) in CKD advancing are 
becoming an important therapeutic task in CKD patients. It can contribute not only in the 
prevention of SGPT but of CVC in CKD.
In our study [51], in the group of CKD 5D, patients who managed to reach and maintain 
the target level of serum phosphorus (0.9–1.45 mmol/L), compared to the matched group of 
patients with uncorrected hyperphosphatemia (>1.45 mmol/L), lower FGF-23 and PTH (p < 
0.01 and p < 0.05 respectively) in serum were noted, mainly among those patients who used 
phosphate-binding drugs that did not contain calcium (sevelamer hydrochloride) for correc-
tion of hyperphosphatasemia.
Among 17 patients who received low-protein diet (LPD) in combination with phosphate 
binders for at least 12 months before starting HD and who achieved the target level of serum 
phosphorus during the first year of treatment with regular HD, the formation of SGPT was 
noted significantly less (χ2 = 8, 2; p < 0.05) than among those patients who has begun correc-
tion of elevated serum phosphorus simultaneously starting with haemodialysis treatment. In 
these patients, CVC such as worsening of the functional class of angina pectoris, acute coro-
nary syndrome and acute myocardial infarction [51] were also reliably less noted.
In experimental studies, increased Klotho expression was accompanied by a decrease in pro-
teinuria and a significant decrease in angiotensin II in the hypertensive chronic glomerulone-
phritis mice [54, 55].
Data on the role of the asymmetric dimethylarginine complex 17/transforming growth 
factor-α/endothelial growth factor (ADAM17/TGF-α/EGFR) induced both due to renin-
angiotensin system (RAS) activation and calcitriol deficiency, in the restructuring of the PTGs 
and in the decrease of Klotho expression in kidneys, allows to suggest the importance of the 
effective blockade of RAS by renin angiotensin blockers as well as D-hormone deficiency 
correction for the prevention and treatment of SGPT [55]. Our preliminary results [53, 56] 
confirm the experimental studies on the ability of AT II blockers to maintain the renal produc-
tion of sKlotho protein.
It has been reported that angiotensin II and aldosterone, through the initiation of oxidative 
stress, have the ability to low Klotho expression in rat kidneys, even in minimal concentra-
tions, while exogenous sKlotho infusion contributed to the inversion of renal damage caused 
by angiotensin II [55].
In our study in patients with CKD stages 1–5D [56] when comparing the patients with hyper-
tension who were receiving antihypertensive monotherapy, the highest serum levels of Klotho 
protein were observed in those of them whose target BP level was achieved primarily through 
angiotensin II receptor blockers, compared to those who were administered with another drug 
group or have not reached the target blood pressure level (p = 0.008 and p = 0.067 respectively).
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On experimental model of mice with CKD and arterial hypertension (AH), it was established 
that one of the mechanisms of sKlotho cardioprotection is also its ability to block the calcium 
channels in cardiomyocytes (TRPC6) that contributes to more adequate correction of AH and 
slower remodelling of the left ventricular myocardium [57].
A number of studies have shown that hypoxia due to anaemia is an independent factor of 
sKlotho protein production reduction as CKD advances [5, 6, 14]. According to our data, in 
patients with CKD with anaemia who managed to reach the target haemoglobin with the help 
of epoetin and iron and maintain it in this range and, as a result, eliminating the hypoxia of vital 
organs, including the kidneys, the preservation of decreasing of sKlotho protein was noted [58].
According to the results of our study [52], the use of Low Protein Diet (LPD) in combination 
with keto/amino acids, during not less than 12 months, in patients with 3B–4 stages of CKD, 
can prevent the development of nutritional status disorders, as well as stimulate sKlotho 
expression and suppress FGF-23 production. In addition, in these group patients, impair-
ment of vascular damping function (according to the assessment of pulse wave velocity and 
augmentation indices by «SphygmoCor» device) as well as cardiac (by EchoCG, semiquan-
titative scale) and aorta calcification (by Kauppila method), and the formation of LVH, was 
less common.
In addition, according to our data, in patients with CKD 3B–4 stages using of LPD (0.6 g pro-
tein per kg body weight/day) supplemented with calcium salts of keto acids, it was possible 
to achieve and maintain the target level of serum phosphorus and calcium by using lower 
doses of phosphate-binding drugs, compared with the patients who used LPD, but did not 
take keto/amino acids [51, 52].
Maintenance of the phosphorus and calcium target serum levels can be a factor that inhibits 
FGF-23 overproduction and reduces the risk of ectopic mineralization and FGF-23-dependent 
LVH in CKD 3B–4 stages [51].
It is known that sKlotho paracrine functions include the activation of calcium channel recep-
tors (TRPVs), especially TRPV5 and TRPV6 [14, 59]. TRPV5 are located mainly in the distal 
renal tubules and participate in the reabsorption of calcium in the kidneys [14]. TRPV6 is 
expressed in intestinal epithelial cells, where it is involved in the intestinal calcium absorp-
tion [14, 59]. In mice with a defect in Klotho gene expression, an increase in the serum level of 
phosphorus and calcium was revealed [5, 14]. Taking into account the participation of sKlotho 
in providing the constancy of serum calcium concentration by changing its reabsorption in 
the kidneys and intestines, it can be assumed that as a result of the intake of calcium salts of 
keto acids, it is possible to stimulate sKlotho production with its effect on the prevention of 
transient hypercalcaemia episodes in CKD advancement.
4. Conclusion
Understanding of the role of Klotho, FGF-23 and sclerostin in CKD is important, because 
it is known that mortality from cardiovascular complications in 20-year-old patients with 
 terminal kidney disease is comparable with such of 80-year-old subjects in total population 
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[2]. And this very high mortality risk cannot be explained solely by influence of traditional 
CVD risk factors, which are highly prevalent in patients with CKD as well as by traditional 
CKD factors such as phosphorus and PTH, correction of which did not result to enough ben-
eficial effects on cardiovascular survival.
Initial disturbances of mineral bone metabolism begin early, already with 3A stage of CKD, 
with an increase in serum FGF-23 and sclerostin and decrease of Klotho levels. The mani-
festation of these early changes may be as an increase in phosphorus excretion. From this 
moment, cardiovascular risk begins to be pawned, although the levels of phosphorus and 
PTH in serum are usually normal yet.
The accumulated data allow to consider the disturbances in FGF-23-Klotho-sclerostin ratio as 
one of the early markers of CKD advancement, disorders of mineral metabolism developing 
and cardiovascular prognosis. Alteration of the FGF-23/sKlotho/sclerostin ratio in serum as 
CKD advancement is accompanied by the development of vascular calcification, formation of 
cardiac remodelling and increasing risk of death from cardiovascular events, independently 
of the serum phosphorus and PTH levels. Changing the ratio of FGF-23, sKlotho and scleros-
tin can be regarded as independent early marker of cardiovascular and overall prognosis of 
patients with CKD.
In the reduction of Klotho expression in the kidneys, the role of ischemia, oxidative stress, 
intracellular elevation of angiotensin II and inflammation was established. These changes 
require careful correction to maintain Klotho’s production as a potent strong cardio-renopro-
tective factor.
The preliminary results obtained on the positive effects of hypertension and anaemia cor-
rection on sKlotho protein maintenance, as well as the possibility of the FGF-23 overproduc-
tion suppression by correcting hyperphosphatemia, demonstrate the need for a personalized 
approach to the choice of cardio-renoprotective therapy from the early stages of CKD based 
on the degree of morphogenetic proteins and sclerostin system dysfunction as well as open 
prospects for studying of cardio-nephroprotective strategy in the new aspect.
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